

Schaffhausen, April 15, 2014

**Announcement according to Art. 9 and Art. 21 SESTO-FINMA  
Disclosure of shareholdings**

Pursuant to Art. 9 and Art. 21 SESTO-FINMA, The Bank of New York Mellon Corporation, New York, USA, has announced to BB Biotech AG, Schaffhausen, Switzerland on April 11, 2014, that its holding in registered shares BB Biotech AG (ISIN CH0038389992) decreased to below than 5% of the proportion of voting rights on April 10, 2014.

The Bank of New York Mellon Corporation, New York, USA, held 536 138 voting rights (4.52% of the proportion of voting rights) as per April 10, 2014, indirectly by the companies listed below:

**Direct Holders:**

- Newton Investment Management Ltd., London, England
- BNY Mellon Service Kapitalanlage-Gesellschaft mbH, Frankfurt am Main, Germany
- Meriten Investment Management GmbH, Düsseldorf, Germany

**Indirect Holders:**

- The Bank of New York Mellon, New York, USA
- MBC Investments Corporation, Delaware, USA
- BNY Mellon International Asset Management Group Limited, London, England
- Newton Management Limited, London, England
- The Bank of New York Mellon SA/NV, Brussels, Belgium
- Mellon JV Limited, London, England
- BNY Mellon Investment Management Holdings (Germany) Limited, London, England
- BNY Mellon Investment Management (Jersey) Limited, St Helier, Jersey
- BNY Mellon Investment Management (Europe) Limited, London, England
- BNY Mellon Investment Management Europe Holdings Limited, London, England

**For further information, please contact:**

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland  
Tanja Chicherio, Tel. +41 44 267 67 07, [tch@bellevue.ch](mailto:tch@bellevue.ch)  
[www.bbbiotech.com](http://www.bbbiotech.com)

**Company profile**

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with CHF 2.1 billion in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.